JP2018532757A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532757A5 JP2018532757A5 JP2018522750A JP2018522750A JP2018532757A5 JP 2018532757 A5 JP2018532757 A5 JP 2018532757A5 JP 2018522750 A JP2018522750 A JP 2018522750A JP 2018522750 A JP2018522750 A JP 2018522750A JP 2018532757 A5 JP2018532757 A5 JP 2018532757A5
- Authority
- JP
- Japan
- Prior art keywords
- ctla
- pharmaceutical composition
- vaccine
- cancer
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 12
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 229960005486 vaccine Drugs 0.000 claims 7
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 5
- 108020001507 fusion proteins Proteins 0.000 claims 5
- 102000037865 fusion proteins Human genes 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108010041986 DNA Vaccines Proteins 0.000 claims 1
- 229940021995 DNA vaccine Drugs 0.000 claims 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 238000009175 antibody therapy Methods 0.000 claims 1
- 238000003782 apoptosis assay Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000005522 programmed cell death Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250984P | 2015-11-04 | 2015-11-04 | |
| US62/250,984 | 2015-11-04 | ||
| PCT/CN2016/104763 WO2017076360A1 (en) | 2015-11-04 | 2016-11-04 | Title of the invention combination therapy for malignant diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018532757A JP2018532757A (ja) | 2018-11-08 |
| JP2018532757A5 true JP2018532757A5 (enExample) | 2019-07-25 |
| JP7148399B2 JP7148399B2 (ja) | 2022-10-05 |
Family
ID=58662444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522750A Active JP7148399B2 (ja) | 2015-11-04 | 2016-11-04 | 悪性疾患に対する併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11684656B2 (enExample) |
| EP (1) | EP3371210B1 (enExample) |
| JP (1) | JP7148399B2 (enExample) |
| CN (1) | CN108699128A (enExample) |
| TW (1) | TWI705972B (enExample) |
| WO (1) | WO2017076360A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100467T1 (it) | 2015-04-17 | 2021-09-14 | Alpine Immune Sciences Inc | Proteine immunomodulatorie con affinità regolabili |
| AU2017248830B2 (en) | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| SG11201808457PA (en) | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| EP3694870A1 (en) * | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| SG11202006148UA (en) * | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| CN113727998A (zh) | 2018-11-30 | 2021-11-30 | 高山免疫科学股份有限公司 | Cd86变体免疫调节蛋白及其用途 |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| KR20050109489A (ko) | 2003-02-13 | 2005-11-21 | 화이자 프로덕츠 인크. | 항-인슐린양 성장인자 ｉ 수용체 항체의 용도 |
| GB0303663D0 (en) * | 2003-02-18 | 2003-03-19 | Lorantis Ltd | Assays and medical treatments |
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| CA2840170A1 (en) * | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
| US8609625B2 (en) * | 2011-06-24 | 2013-12-17 | Taipei Veterans General Hospital | Method for enhancing immune response in the treatment of infectious and malignant diseases |
| US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| CA2889182A1 (en) * | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| MX428954B (es) | 2013-03-15 | 2025-11-13 | Univ Pennsylvania | Vacunación mejorada contra la hormona liberadora de la hormona de crecimiento (ghrh) humana. |
| CN104761633B (zh) * | 2015-03-25 | 2018-11-27 | 新乡学院 | 阻断猪pd-1/pd-l1通路的多肽及其应用 |
-
2016
- 2016-11-04 EP EP16861628.2A patent/EP3371210B1/en active Active
- 2016-11-04 JP JP2018522750A patent/JP7148399B2/ja active Active
- 2016-11-04 WO PCT/CN2016/104763 patent/WO2017076360A1/en not_active Ceased
- 2016-11-04 TW TW105136056A patent/TWI705972B/zh active
- 2016-11-04 US US15/773,433 patent/US11684656B2/en active Active
- 2016-11-04 CN CN201680064281.4A patent/CN108699128A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lu et al. | Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party | |
| Cheng et al. | Recent advances in small molecule based cancer immunotherapy | |
| Pandey et al. | Revolutionization in cancer therapeutics via targeting major immune checkpoints PD-1, PD-L1 and CTLA-4 | |
| Liu et al. | Synergistic immuno photothermal nanotherapy (SYMPHONY) for the treatment of unresectable and metastatic cancers | |
| Zamani et al. | Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies? | |
| Zhang et al. | Trigger inducible tertiary lymphoid structure formation using covalent organic frameworks for cancer immunotherapy | |
| Hanna et al. | Immune modulation in advanced radiotherapies: targeting out-of-field effects | |
| JP2016513458A5 (enExample) | ||
| JP2019517788A5 (enExample) | ||
| Ostios-Garcia et al. | Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer | |
| Li et al. | Immunotherapy in colorectal cancer: Statuses and strategies | |
| JP2018537536A5 (enExample) | ||
| Schmidt et al. | A killer choice for cancer immunotherapy | |
| Duenas-Gonzalez et al. | Pharmacodynamics of current and emerging treatments for cervical cancer | |
| Park et al. | Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy | |
| Veneziani et al. | Antibody–drug conjugates: advancing from magic bullet to biological missile | |
| Chen et al. | Allogeneic CAR-T cells for cancer immunotherapy | |
| Tian et al. | Programing immunogenic cell death in breast tumors with designer DNA frameworks | |
| Li et al. | Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody− Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects | |
| Glitza Oliva et al. | Immunotherapy for melanoma | |
| Vandghanooni et al. | Aptamedicine: a new treatment modality in personalized cancer therapy | |
| Lok et al. | Immunotherapies in breast cancer: harnessing the cancer immunity cycle | |
| Kovacevic et al. | Copper that cancer with lysosomal love! | |
| Azizi et al. | T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments | |
| Hoesli et al. | Immunotherapy for head and neck squamous cell carcinoma |